Virginia Economic Review

Brent Ward likes challenging projects. As a co-founder of design firm Riggs Ward, his job is to help bring stories to life, through displays of artifacts, graphics, soundscapes, and interactive digital media.

For more than 300 years, Virginia’s universities have helped produce generations of political leaders, scientists, entrepreneurs, engineers, and business executives who shaped the economy in the Commonwealth and beyond.

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia.

Eric Arocho is associate vice president at Eli Lilly and Company and the site lead on the company’s facility in Goochland County, announced last year.

In October 2025, shovels went into the ground in Elkton, marking the start of a $3 billion pharmaceutical expansion project that will add 400,000 square feet to Merck’s existing campus.

The Greater Richmond region is in the middle of the greatest population growth in its history.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?

The I95-I85 Intersection is anchored by the Tri-Cities of Petersburg (home to Civica Rx’s facility that produces a wide variety of affordable essential medicines), Hopewell, and Colonial Heights.

A lot changed in Virginia’s life sciences industry in the space of about a month last fall. Between Sept. 16 and Oct. 20, biopharmaceutical manufacturing giants Eli Lilly and Company, AstraZeneca, and Merck & Co.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

A pharmaceutical manufacturing innovation that came out of a Virginia university is changing the way medicines are made. The Commonwealth’s universities and the rest of its biopharma research community are making sure Virginia is ready to make the medicines of the future.

Would more men try to prevent unintended pregnancies if their choices for contraception went beyond a condom or vasectomy?